TB medicine pretomanid enters regulatory review process in the United States

(Burness) TB Alliance's new drug application (NDA) for the novel tuberculosis (TB) drug candidate pretomanid has been accepted for review by the United States Food and Drug Administration (FDA).

https://www.eurekalert.org/pub_releases/2019-03/b-tmp030719.php

Source: EurekAlert! - Infectious and Emerging Diseases - March 8, 2019 Category: Infectious Diseases Source Type: news

More News: Food and Drug Administration (FDA) | Infectious Diseases | New Drug Applications | Tuberculosis | USA Health